Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022

- Conference Call Scheduled for Tuesday, April 26, 2022 at 4:30 p.m. ET -

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that the company will release full year 2021 financial results on Tuesday April 26, 2022 after the close of market. Ambrx will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

Individuals interested in listening to the conference call may do so by dialing (844) 200-6205 for domestic callers, or (929) 526-1599 for international callers and reference access code: 9264119; or from the webcast link in the investor relations section of the company's website at: www.ambrx.com.

A webcast replay of the call will be available beginning April 26, 2022 at 4:30 p.m. PT / 7:30 p.m. ET. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.

About Ambrx Biopharma Inc. (Ambrx)

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology. For more information, please visit www.ambrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005995/en/